Friday 6 November 2026 Export IMNN’s income statement to Excel — free account

Imunon, Inc.

IMNN Healthcare Biotechnology

Imunon, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $500,000.00.

EPS: +74.9%
Free cash flow: −4.24%

Quarter to June 2026, against a year earlier

Operating cash flow growth 3 yrs

0.85 0.05 −5.56%

Follow IMNN

Alert me

Market cap: $5.1M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 2/9
Altman Z: −12.52
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 0.04

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	1	2	3	—	—	—

Insider Ownership 8.08%

Capital & Financial Ratios $m

Size

Market Cap 5.05

Revenue ttm 0.50

Net income ttm (14.71)

Free cash flow ttm (15.20)

Net debt Q (1.33)

Valuation

P/E 0.00

Forward P/E (0.51)

Price / sales 8.90

Forward P/S Powerpack

Price / FCF 0.00

Price / book 2.30

Financial health

Current ratio Q 1.82

Debt / equity Q 1.32

Interest coverage Q (36.11)

Growth

Revenue growth Q 0.00%

Operating income growth Q −0.85%

EPS, this year +65.42%

EPS, next year A +22.95%

Revenue, next year A −66.00%

EPS, past 5 yrs —

EPS, next 5 yrs A +41.53%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.32%

10-year low 10-year high

P/B against its own 10 years 76.03%

10-year low 10-year high

EV/Sales against its own 10 years 10.44%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	16	6	9	7
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	3	2	2	2
	18	8	11	9

	2023	2024	2025	Q'26
Payables	4	1	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	7	5	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	(12.94%)	0.00%	0.00%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(10.06%)	(17.62%)	(37.79%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.94 Actual −0.54

−1.91 −1.52 −1.13 −0.75 −0.36

Q3 FY25 Beat +0.57

Q4 FY25 Beat +0.14

Q1 FY26 Beat +0.44

Q2 FY26 Beat +0.40

Q3 FY26 — Nov 12

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−1.73	−1.16	Beat by 0.57
Q4 FY25	−1.43	−1.29	Beat by 0.14
Q1 FY26	−1.28	−0.84	Beat by 0.44
Q2 FY26	−0.94	−0.54	Beat by 0.40
Q3 FY26	−0.61	—	Reports 12 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.84)	(0.54)	—	—	—
’25	(3.15)	(2.15)	(1.16)	(1.29)	(6.83)
’24	(7.87)	(7.64)	(3.76)	(2.19)	(16.94)
’23	(10.20)	(9.15)	(5.55)	(7.81)	(32.40)
’22	(27.30)	(13.05)	(13.05)	(22.76)	(75.45)
’21	(49.62)	(14.27)	(13.49)	(7.46)	(57.45)
’20	(44.98)	(40.48)	(53.97)	(21.21)	(150.67)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	0	0	0	0	1
’21	0	0	0	0	1
’20	0	0	0	0	1
’19	0	0	0	0	1
’18	0	0	0	0	1
’17	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(3)	(3)	(4)	(4)	(14)
’24	(6)	(5)	(4)	(4)	(19)
’23	(4)	(7)	(4)	(4)	(19)
’22	(8)	(5)	(5)	(5)	(23)
’21	(5)	(3)	(4)	(5)	(16)
’20	(5)	(3)	(4)	(4)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(3)	(3)	(4)	(4)	(14)
’24	(6)	(5)	(4)	(4)	(19)
’23	(4)	(7)	(5)	(4)	(19)
’22	(8)	(6)	(5)	(5)	(23)
’21	(5)	(3)	(4)	(5)	(17)
’20	(5)	(3)	(4)	(4)	(16)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	1	1	1	1	1	1	1	—	—	—	1		0.0%	9	9	9	0.0%
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—	—	—	0.00		0.0 pt	Powerpack Imunon, Inc.’s next three years, line by line Analysts expect revenue to grow 0.0% a year to 2028 — in line with the 0.0% of the last 6 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(22)	(20)	(22)	(19)	(23)	(22)	(37)	(21)	(19)	(14)	(15)		(4.6%)
	EBT margin, %	(4,410.74)	(4,080.44)	(4,460.50)	(3,733.60)	(4,665.88)	(4,430.54)	(7,493.06)	0.00	0.00	0.00	0.00		+4,410.7 pt
	Net income	(22)	(20)	(12)	(17)	(21)	(21)	(36)	(20)	(19)	(14)	(15)		(4.6%)
Per share, $
Per share, $	Revenue	60.56	14.75	6.39	5.15	3.52	1.38	1.05	0.00	0.00	0.00	0.00		n/m
	Earnings	(2,677.22)	(611.69)	(152.92)	(173.16)	(150.67)	(57.45)	(75.45)	(32.40)	(16.94)	(6.83)	(3.83)		(48.5%)
	Cash flow	(2,225.98)	(490.97)	(90.02)	(208.68)	(109.98)	(44.84)	(48.50)	(31.54)	(17.16)	(6.54)	(2.89)		(47.7%)
	Capex	(7.57)	(1.14)	(1.77)	(3.60)	(0.13)	(0.86)	(0.56)	(0.75)	(0.03)	(0.13)	(0.02)		(36.2%)
	Free cash flow	(2,233.55)	(492.11)	(91.79)	(212.28)	(110.11)	(45.70)	(49.07)	(32.29)	(17.18)	(6.68)	(2.90)		(47.6%)
	Book value	814.58	787.83	266.69	149.97	131.05	154.22	61.59	22.20	3.86	3.33	0.80		(45.7%)
	Shares, m	0	0	0	0	0	0	0	1	1	2	4		+85.3%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	0.00		0.0
	P/S	14.25	37.40	43.15	64.95	39.51	119.57	22.74	—	—	—	8.90		48.8
	P/B	1.06	0.70	1.03	2.23	1.06	1.07	0.39	—	—	—	2.30		1.1
	EV/Sales	8.28	(8.30)	6.76	51.16	13.05	32.50	(36.53)	—	—	—	6.23		9.6
	EV/FCF	(0.22)	0.25	(0.47)	(1.24)	(0.42)	(0.98)	0.78	—	—	—	(0.21)		(0.3)
Cash, $m
Cash, $m	Operating cash flow	(18)	(17)	(7)	(20)	(16)	(16)	(23)	(19)	(19)	(14)	(15)		(3.1%)
	Capex	0	0	0	0	0	0	0	0	0	0	0		+18.2%
	Free cash flow	(18)	(17)	(7)	(21)	(16)	(17)	(23)	(19)	(19)	(14)	(15)		(2.9%)
Balance, $m
Balance, $m	Working capital	(4)	18	22	8	12	45	27	11	3	6	4		n/m
	Net debt	(4)	(24)	(18)	(7)	(13)	(44)	(30)	(16)	(6)	(9)	(1)		+8.2%
	Shareholders’ equity	7	27	21	15	19	56	29	13	4	7	4		+0.5%
Returns, %
Returns, %	ROA	(55.22)	(52.95)	(25.18)	(39.59)	(56.68)	(37.23)	(60.83)	(59.23)	(117.72)	(131.74)	(123.93)		(76.5) pt
	ROIC	(532.96)	(455.08)	(493.72)	(167.77)	(214.70)	(107.08)	0.00	0.00	0.00	0.00	(324.37)		+533.0 pt
	ROE	(162.69)	(124.13)	(49.97)	(95.15)	(129.54)	(55.83)	(84.34)	(91.37)	(211.21)	(256.41)	(641.02)		(93.7) pt
People
People	Employees	19	21	29	29	27	29	31	33	25	20	—		+0.6%
	Revenue/emp, $m	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2022 · latest quarter Dec 2022 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ACXP Acurx Pharmaceuticals, Inc.	$5.3M	— (loss-making)	—	—	n/m	−2.36% (below 0%: shrinking)	—	0.00%	Compare
PCSA Heatwurx Inc.	$5.1M	— (loss-making)	—	−64.29% (below 0%: shrinking)	n/m	+20.29% (above 0%: growing)	0.00%	0.00%	Compare
SNTI Senti Biosciences, Inc.	$5.1M	— (loss-making)	— (loss-making)	−98.68% (below 0%: shrinking)	n/m	−7.48% (below 0%: shrinking)	100.00%	(85,229.41%)	Compare
PULM Pulmatrix, Inc.	$5.1M	— (loss-making)	— (loss-making)	−99.86% (below 0%: shrinking)	n/m	+41.26% (above 0%: growing)	100.00%	0.00%	Compare
CNSY Cerenome, Inc.	$5.1M	— (loss-making)	— (loss-making)	−70.43% (below 0%: shrinking)	n/m	−31.46% (below 0%: shrinking)	100.00%	(2,203.65%)	Compare
IMNN Imunon, Inc.	$5.1M	— (loss-making)	— (loss-making)	0.00%	n/m	−4.24% (below 0%: shrinking)	0.00%	0.00%
RVPH Reviva Pharmaceuticals Holdings, Inc.	$5.0M	— (loss-making)	—	—	n/m	+57.80% (above 0%: growing)	—	0.00%	Compare
CDIO Cardio Diagnostics Holdings, Inc.	$5.0M	— (loss-making)	— (loss-making)	+23.79% (above 0%: growing)	n/m	+2.59% (above 0%: growing)	100.00%	(48,193.84%)	Compare
CANF Can-Fite Biopharma Ltd	$4.9M	— (loss-making)	— (loss-making)	−1.18% (below 0%: shrinking)	n/m	+12.63% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$5.1M	—	—	−67.36%	—	+7.61%	100.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 4 May 2026

Ownership

Directors and executive officers, together 2.83%

Armistice Capital, LLC 8.78%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Imunon, Inc. (IMNN) Latest News

6 Nov

Impact 3 · 9:00 AM · GlobeNewswire

IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer

21 Oct

Impact 4 · 8:15 AM · GlobeNewswire

IMUNON Announces Strategic Sale of ThermoDox®

1 Oct

Impact 4 · 11:40 AM · Zacks Small Cap Research

IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer

29 Sep

Impact 3 · 8:00 AM · GlobeNewswire

IMUNON Converts $1.2 Million of Debt-to-Equity

24 Sep

Impact 4 · 8:05 AM

IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

22 Sep

Impact 4 · 8:05 AM · GlobeNewswire

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

10 Sep

Impact 4 · 9:30 AM

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

26 Aug

Impact 3 · 8:30 AM

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

19 Aug

Impact 4 · 8:10 AM

IMNN: Strong Enrollment Momentum Continuing for Phase 3 OVATION 3 Trial

11 Aug

Impact 3 · 10:12 PM · The Motley Fool transcript

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Impact 3 · 12:52 PM · Moby transcript

Imunon, Inc. Q2 2026 Earnings Call Summary

Impact 3 · 8:00 AM

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

30 Jul

Impact 4 · 9:00 AM

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

Impact 4 · 8:30 AM

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study

21 Jul

Impact 4 · 9:00 AM

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

Impact 4 · 8:30 AM

Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients

23 Jun

Impact 3 · 8:00 AM · GlobeNewswire

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

5 Jun

Impact 4 · 6:40 AM · Zacks Small Cap Research

IMNN: $10 Million Financing to Advance Phase 3 OVATION 3 Trial

4 Jun

Impact 4 · 10:32 AM · InvestorsHub

Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)

Impact 3 · 8:00 AM · GlobeNewswire

IMUNON Announces Up to $10 Million Cash Financing

1 Jun

Impact 3 · 11:47 AM · The Motley Fool transcript

Imunon IMNN Q4 2025 Earnings Transcript

14 May

Impact 4 · 11:53 AM · Zacks Small Cap Research

IMNN: On Track to Have 80 Patients Enrolled in Phase 3 OVATION 3 Trial by 1Q27

13 May

Impact 3 · 8:30 AM · Moby transcript

Imunon, Inc. Q1 2026 Earnings Call Summary

12 May

Impact 4 · 7:00 PM · GuruFocus.com

Imunon Inc (IMNN) Q1 2026 Earnings Call Highlights: Promising Clinical Progress Amidst Funding ...

Impact 4 · 12:13 PM · The Motley Fool transcript

Imunon (IMNN) Q1 2026 Earnings Transcript

Impact 3 · 8:00 AM · GlobeNewswire

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

1 Apr

Impact 4 · 7:15 AM

IMNN: Enrollment in Phase 3 OVATION 3 Trial Remains Ahead of Schedule

Impact 3 · 8:30 AM · Moby

Imunon, Inc. Q4 2025 Earnings Call Summary

31 Mar

Impact 4 · 5:00 PM · GuruFocus.com

Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Management

Impact 4 · 8:00 AM · GlobeNewswire

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

Imunon, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Imunon, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 4 May 2026

Ownership

Imunon, Inc. (IMNN) Latest News

6 Nov

21 Oct

1 Oct

29 Sep

24 Sep

22 Sep

10 Sep

26 Aug

19 Aug

11 Aug

30 Jul

21 Jul

23 Jun

5 Jun

4 Jun

1 Jun

14 May

13 May

12 May

1 Apr

31 Mar

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Imunon, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 4 May 2026

Ownership

Imunon, Inc. (IMNN) Latest News

6 Nov

21 Oct

1 Oct

29 Sep

24 Sep

22 Sep

10 Sep

26 Aug

19 Aug

11 Aug

30 Jul

21 Jul

23 Jun

5 Jun

4 Jun

1 Jun

14 May

13 May

12 May

1 Apr

31 Mar

Stockrow Weekly